Objectives:
Alzheimer's disease (AD) is a growing global health crisis exacerbated by increasing life span and an aging demographic. Convergent lines of evidence, including genome-wide association studies, strongly implicate
neuroinflammation in the pathogenesis of AD. Several dietary agents, including phenolic-rich foods, show promise for the prevention and/or management of AD, which in large part, has been attributed to their anti-inflammatory effects. We previously reported that a food-grade phenolic-enriched maple syrup extract (MSX) inhibited
neuroinflammation in vitro but whether these effects are translatable in vivo remain unknown. Herein, we assessed MSX's ability to attenuate early
neuroinflammation in a transgenic mouse model of AD.Methods: The effects of MSX on AD-related
neuroinflammation was evaluated by orally administering MSX (100 and 200 mg/kg/day for 30 days) to the 3xTg-AD mouse model of AD. The expression of inflammatory markers in mouse brains were analyzed with LC-MS/MS with SWATH acquisition.Results: 3xTg-AD mice dosed orally with MSX have decreased expression of several inflammatory
proteins, including, most notably, the AD risk-associated
protein 'triggering receptor expressed on myeloid cells-2' (TREM2), and stimulator of
interferon genes TMEM173, and suppressor of
cytokine signaling-6 (SOCS6). However, this decrease in
inflammation did not coincide with a decrease in pathogenic
amyloid generation or lipid peroxidation.Discussion: These data demonstrate that
oral administration of this maple syrup derived natural product reduces key neuroinflammatory indices of AD in the 3xTg-AD model of AD. Therefore, further studies to investigate MSX's potential as a dietary intervention strategy for AD prevention and/or management are warranted.